Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2018
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2018'; Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosphoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter of these genes.
The report 'Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2018' outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 1, 1 and 2 respectively.
Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Brain Tumor, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection, Liver Transplant Rejection, Lymphoma, Medulloblastoma, Multiple Myeloma (Kahler Disease), Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma and Recurrent Medulloblastoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2018'; Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - 65-kDa cytosolic phosphoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter of these genes.
The report 'Human cytomegalovirus 65 kDa Phosphoprotein - Pipeline Review, H2 2018' outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 1, 1 and 2 respectively.
Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Brain Tumor, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection, Liver Transplant Rejection, Lymphoma, Medulloblastoma, Multiple Myeloma (Kahler Disease), Recurrent Glioblastoma Multiforme (GBM), Recurrent Malignant Glioma and Recurrent Medulloblastoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
- The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects
- The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development
Hookipa Biotech AG
Immunomic Therapeutics Inc
Vakzine Projekt Management GmbH
Vaximm AG
VBI Vaccines Inc
Vical Inc
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme, Medulloblastoma and Recurrent Malignant Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyMVectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Triplex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPM-2001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXM-65 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones
Featured News & Press Releases
Apr 17, 2018: VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
Jan 17, 2018: VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
Nov 22, 2017: Dr. Duane Mitchell Reports Findings of Study Aimed at Aggressive Brain Cancer
Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress
Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood
Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Overview
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Companies Involved in Therapeutics Development
Hookipa Biotech AG
Immunomic Therapeutics Inc
Vakzine Projekt Management GmbH
Vaximm AG
VBI Vaccines Inc
Vical Inc
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Drug Profiles
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme, Medulloblastoma and Recurrent Malignant Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CyMVectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Triplex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBI-1901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPM-2001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VXM-65 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Dormant Products
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Discontinued Products
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) - Product Development Milestones
Featured News & Press Releases
Apr 17, 2018: VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
Jan 17, 2018: VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
Nov 22, 2017: Dr. Duane Mitchell Reports Findings of Study Aimed at Aggressive Brain Cancer
Nov 10, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients
Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit
Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus
Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress
Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood
Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Hookipa Biotech AG, H2 2018
Pipeline by Immunomic Therapeutics Inc, H2 2018
Pipeline by Vakzine Projekt Management GmbH, H2 2018
Pipeline by Vaximm AG, H2 2018
Pipeline by VBI Vaccines Inc, H2 2018
Pipeline by Vical Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Hookipa Biotech AG, H2 2018
Pipeline by Immunomic Therapeutics Inc, H2 2018
Pipeline by Vakzine Projekt Management GmbH, H2 2018
Pipeline by Vaximm AG, H2 2018
Pipeline by VBI Vaccines Inc, H2 2018
Pipeline by Vical Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Hookipa Biotech AG
Immunomic Therapeutics Inc
Vakzine Projekt Management GmbH
Vaximm AG
VBI Vaccines Inc
Vical Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Hookipa Biotech AG
Immunomic Therapeutics Inc
Vakzine Projekt Management GmbH
Vaximm AG
VBI Vaccines Inc
Vical Inc
